Sign In
Buy AXSM
$212.17
+1.13 (+0.535%)
At Close: Aug 04, 2026
Axsome (AXSM) Plans NDA Filing for Fibromyalgia Drug in 2022
09:01am, Wednesday, 16'th Jun 2021
Axsome (AXSM) concludes a favorable pre-NDA meeting with the FDA for AXS-14, which is being developed as a treatment of fibromyalgia. The company will file an NDA in the fourth quarter of 2022.
Axsome Therapeutics Targets Submission Of US Application For Fibromyalgia Candidate By 2022
09:34am, Tuesday, 15'th Jun 2021
After a pre-NDA meeting with FDA, Axsome Therapeutics Inc (NASDAQ: AXSM) has announced its plan to submit a marketing application seeking approval for AXS-14 to manage fibromyalgia. The submission
2 Top Biotech Stocks to Buy for Summer 2021
06:31am, Saturday, 05'th Jun 2021
Progress in these companies' drug development pipelines should give shareholders plenty to look forward to.
Axsome Therapeutics: PDUFA Ahead
08:06am, Thursday, 03'rd Jun 2021
Axsome has a PDUFA on August 22.
Axsome's (AXSM) Q1 Earnings Top, AXS-05 Launch in Focus
12:02pm, Tuesday, 11'th May 2021
Axsome (AXSM) reports narrower-than-expected loss for the first quarter of 2021. The company is gearing up to launch its first commercial product, AXS-05, following a potential approval.
Axsome Therapeutics, Inc. (AXSM) CEO Herriot Tabuteau on Q1 2021 Results - Earnings Call Transcript
12:52pm, Monday, 10'th May 2021
Axsome Therapeutics, Inc. (AXSM) CEO Herriot Tabuteau on Q1 2021 Results - Earnings Call Transcript
Why Earnings Season Could Be Great for Axsome Therapeutics (AXSM)
09:46am, Friday, 07'th May 2021
Axsome Therapeutics (AXSM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
NEW YORK, May 07, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) is joining Mental Health America (MHA) and other advocacy organizations in observing May is Mental Health Month, by
Why Voyager Therapeutics, uniQure, Axsome, Reviva Pharma and Crispr Are Moving Today
02:18pm, Monday, 26'th Apr 2021
Voyager Therapeutics, Inc. (NASDAQ: VYGR), uniQure N.V. (NASDAQ: QURE), Axsome Therapeutics, Inc. (NASDAQ: AXSM), Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) and CRISPR Therapeutics AG (NASDAQ
Why Axsome Therapeutics Stock Is Jumping Today
12:16pm, Monday, 26'th Apr 2021
The FDA granted Priority Review to the biotech's regulatory filing for its lead pipeline candidate.
Axsome Stock Jumps After Snagging Priority Review For Depression Drug
11:29am, Monday, 26'th Apr 2021
Axsome Therapeutics snagged a speedy review from the Food and Drug Administration for its depression treatment, known as AXS-05, on Monday, leading Axsome stock to gap higher. The post Axsome Stock Ju
AXSM Stock: Over 5% Increase Pre-Market Explanation
06:40am, Monday, 26'th Apr 2021
The stock price of Axsome Therapeutics, Inc. (NASDAQ: AXSM) increased by over 5% pre-market. This is why it happened.
FDA grants Priority Review and sets PDUFA action goal date of August 22, 2021
Why Is Axsome (AXSM) Down 19.9% Since Last Earnings Report?
12:07pm, Wednesday, 31'st Mar 2021
Axsome (AXSM) reported earnings 30 days ago. What's next for the stock?
Axsome: Robust Fundamental Improvements
04:02pm, Thursday, 18'th Mar 2021
The crown jewel (AXS-05) is poised to gain its first FDA approval as a treatment for major depressive disorder.
